Clinical validation of the Intermediate-risk NMIBC Scoring System and Substratification Model

Clinical validation of the Intermediate-risk NMIBC Scoring System and Substratification Model

European Urology Oncology shared an article by Francesco Soria on X:

“Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group by Francesco Soria, et al.”

 Clinical validation of the Intermediate-risk NMIBC Scoring System and Substratification Model

Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration.

Authors: Francesco Soria, et al.

Clinical validation of the Intermediate-risk NMIBC Scoring System and Substratification Model